Literature DB >> 8943701

Selective absence of cone outer segment beta 3-transducin immunoreactivity in hereditary cone degeneration (cd).

K E Gropp1, A Szél, J C Huang, G M Acland, D B Farber, G D Aguirre.   

Abstract

We have used immunocytochemistry and in situ hybridization to examine the expression of photoreceptor specific genes in retinas of normal dogs and those affected with hereditary cone degeneration (cd), a rare autosomal recessive disorder that selectively affects cones. In the cd retina, cone disease begins early in life; cones are lost by extrusion of the nucleus into the inner segment, and later by displacement of the nucleus, surrounded by a thin rim of cytoplasm, into the interphotoreceptor space. Two micrometer sections from the superior and inferior retinal meridians, extending from the optic disk to the ora serrata, were used for in situ hybridization with a bovine rod opsin and human red/green cone opsin cRNA probes, or were reacted with antibodies directed against photoreceptor-specific proteins and visualized with appropriate biotinylated antibodies. Antibodies against the following proteins were used: alpha- and beta 3-transducins, phosducin, alpha/beta- and gamma-phosphodiesterases, COS-1, and OS-2, opsin, S-antigen and IRBP. Immunoreactivity or hybridization labeling was evaluated in unstained sections; cone pathology was judged in adjacent Toluidine Blue-stained sections. With these methods it was possible to evaluate immunoreactivity or hybridization labeling and cone pathology at the single cell level. Both middle-(COS-1) and short-(OS-2) wavelength-sensitive cones were present in controls and cd affected retinae at 2.2 months, and distinct transcripts of the red/green cone pigment gene were identified in the majority of cones in both normal and affected retinas at this age. However, beta 3-transducin immunoreactivity was completely absent from cd-affected cone outer segments. Both cone types were present but in reduced numbers in older animals (11.5 and 17 months), and no reactivity to beta 3-transducin was noted. No differences were found with the other antibodies used. The specific absence of beta 3-transducin immunoreactivity from the cone outer segments suggests a potential involvement of the beta 3-transducin gene or gene product in the disease process.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943701     DOI: 10.1006/exer.1996.0117

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  6 in total

Review 1.  The function of dog models in developing gene therapy strategies for human health.

Authors:  Keri L Nowend; Alison N Starr-Moss; Keith E Murphy
Journal:  Mamm Genome       Date:  2011-07-06       Impact factor: 2.957

2.  Gene therapy rescues cone function in congenital achromatopsia.

Authors:  András M Komáromy; John J Alexander; Jessica S Rowlan; Monique M Garcia; Vince A Chiodo; Asli Kaya; Jacqueline C Tanaka; Gregory M Acland; William W Hauswirth; Gustavo D Aguirre
Journal:  Hum Mol Genet       Date:  2010-04-08       Impact factor: 6.150

3.  A new form of inherited red-blindness identified in zebrafish.

Authors:  S E Brockerhoff; J B Hurley; G A Niemi; J E Dowling
Journal:  J Neurosci       Date:  1997-06-01       Impact factor: 6.167

4.  Targeting gene expression to cones with human cone opsin promoters in recombinant AAV.

Authors:  A M Komáromy; J J Alexander; A E Cooper; V A Chiodo; L G Glushakova; G M Acland; W W Hauswirth; G D Aguirre
Journal:  Gene Ther       Date:  2008-03-13       Impact factor: 5.250

Review 5.  Naturally occurring animal models with outer retina phenotypes.

Authors:  Wolfgang Baehr; Jeanne M Frederick
Journal:  Vision Res       Date:  2009-04-16       Impact factor: 1.886

6.  Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia.

Authors:  András M Komáromy; Jessica S Rowlan; Amanda T Parton Corr; Shelby L Reinstein; Sanford L Boye; Ann E Cooper; Amaliris Gonzalez; Britt Levy; Rong Wen; William W Hauswirth; William A Beltran; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2013-04-09       Impact factor: 11.454

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.